{
  "docId": "019de073-7b6a-72bb-8d98-812d56d63617",
  "docSlug": "f8b2787992eb3375620f74057447d0c9",
  "documentTitle": "Aravive | Investor Presentation Deck | 39 slides",
  "authorId": "aravive",
  "authorName": "Aravive",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 39,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "why_now",
  "function": "argue_timing",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Includes qualitative feedback from KOLs and healthcare providers regarding clinical utility and patient selection.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7b6a-72bb-8d98-812d56d63617/35",
  "deckHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617",
  "deckJsonHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617.json",
  "deckAnchorHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.42,
        "x": 0.07,
        "y": 0.48
      },
      "kind": "framework",
      "text": "Desire for Targeted Tx Addressing More Pts: PDAC has limited actionable biomarkers that total <5% of eligible patients, fostering a desire for options that address a greater proportion of patients",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3694a9af-a0a2-4043-8ce2-38f0c70a29dd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.42,
        "x": 0.07,
        "y": 0.68
      },
      "kind": "framework",
      "text": "Improved Efficacy over SOC: Physicians were highly enthusiastic about the improved efficacy over ~3 months (e.g., OS, PFS), especially in the upside case",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56e54a1b-d884-4eb5-8f53-046b6b91f4de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.42,
        "x": 0.07,
        "y": 0.28
      },
      "kind": "framework",
      "text": "Unmet Need for Chemo Alternatives: Lack of agents beyond gem + nab-pac and FOLFIRINOX and limited anticipated competition in PDAC bolsters expected brand share",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef201b5e-afcf-4555-bab1-ecd03404f604",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.35,
        "x": 0.53,
        "y": 0.45
      },
      "kind": "quote",
      "text": "Efficacy in the base case is similar to FOLFIRINOX, I like that it is more tolerable for patients. – Healthcare Provider",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22e6be4e-7d31-4fee-ab71-9730082d0568",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.65,
        "y": 0.65
      },
      "kind": "quote",
      "text": "If I had good results with Product X in my ECOG 0-1 patients, then I would consider utilizing in certain ECOG 2 patients too. – Healthcare Provider",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51fd22e7-5ebc-4e1b-b48c-dc5bb1c3ec44",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.65,
        "y": 0.22
      },
      "kind": "quote",
      "text": "If the biomarker high population were really 70%, I would serum test and give [the upside] to all my positive patients. – KOL",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac55fdbf-1676-43be-a587-c71ec633df5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.55,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Note: physicians' comments based on P1b data",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a85d9340-0d66-4d89-9db2-2b4b90ac6065",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Market Research Suggests Batiraxcept Would Fill an Unmet Need and Be Adopted into the Current PDAC Treatment Paradigm",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d595baa-9e02-4019-8135-0f4b29989e10",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "6782fe01-b7ad-401b-af73-056f87526d5b",
      "evidence": "The slide presents a clear problem (limited actionable biomarkers), an existing solution (current treatment paradigm), and a proposed solution (Batiraxcept), which aligns with the AIDA model's Attention, Interest, Desire, and Action stages.",
      "confidence": 0.7
    },
    {
      "name": "Problem-Agitate-Solve (PAS)",
      "slug": "problem-agitate-solve-pas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "ed3b0379-e4d2-4740-be44-43a1ade7f5ac",
      "evidence": "The slide identifies a problem (limited treatment options for PDAC), agitates it (desire for targeted therapy), and presents a solution (Batiraxcept), which aligns with the PAS framework.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "evidence-matrix",
      "slug": null,
      "matchId": "57d2b7e6-2c5f-4dc5-a51f-26e9a3a54714",
      "evidence": "Structured mapping of unmet needs to physician feedback",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}